Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy
Alan Burnett et al.
Top follicular lymphoma discussion points at ICML 2017
Challenges with the identification of ALL subtypes
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Trial of ibrutinib with bendamustine and rituximab in CLL: results and study design